Scientists at Beigene Ltd. and Beigene Switzerland GmbH have identified phosphatidylinositol 3-kinase α (PI3Kα) (H1047R mutant) inhibitors reported to be useful for the treatment of cancer, congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities and PIK3CA related overgrowth spectrum (PROS).